The diabetes drug class glucagon-like peptide-1 (GLP-1) receptor agonists have constructive heart health outcomes with out main security considerations, analysis shows. University of Oxford scientists performed a meta-analysis of the GLP-1 agonists Lyxumia (lixisenatide), Victoza (liraglutide), Ozempic (semaglutide), and Bydureon (extended-release...